TherapeuticsMD's (TXMD) Estradiol VagiCap vaginal capsule for the treatment of vulvar vaginal atrophy (VVA) in post-menopausal women performed well in two trials when compared with NovoNordisks (NVO) Vagifem.
The results of the studies showed substantially lower systemic exposure to the estradiol hormone of the VagiCap - also known as TX 12-004-HR - vs Vagifem.
VVA affects up to 50% of postmenopausal women and is a result of a decrease in estrogen.
TherapeuticsMD's shares are +7.8%. (PR)